Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

33.41 +0.43 (+1.30%)
Streaming Delayed Price Updated: 11:17 AM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 636,768
Open 32.87
Bid (Size) 33.33 (100)
Ask (Size) 33.49 (100)
Prev. Close 32.98
Today's Range 32.51 - 33.73
52wk Range 18.92 - 43.15
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Forget AI Stocks: This Potentially Disruptive Biotech Could Soar By 181%, According to Wall Street ↗
This stock could make you a fortune in the next two years, or lose you a whole lot of money. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the... 
Via Finterra
Topics Economy Intellectual Property

Performance

YTD
-5.7%
-5.7%
1 Month
+17.5%
+17.5%
3 Month
-12.0%
-12.0%
6 Month
+31.1%
+31.1%
1 Year
+19.5%
+19.5%

More News

Read More
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Via The Motley Fool
News headline image
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗
Via The Motley Fool
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
Via MarketMinute
News headline image
Why Viking Therapeutics Stock Is Up More Than 9% Today ↗
Via The Motley Fool
News headline image
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
Via MarketMinute
News headline image
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
Via MarketMinute
Topics Earnings
News headline image
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗
Via The Motley Fool
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Really Going to $125? ↗
Via The Motley Fool
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
Via MarketMinute
Topics Earnings Economy
News headline image
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗
Via The Motley Fool
News headline image
The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗
Via Stocktwits
News headline image
Viking Therapeutics Stock Soars: What's Driving The Momentum? ↗
Via Benzinga
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Viking (VKTX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings Intellectual Property
Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours ↗
Via Stocktwits
Topics Government Stocks
News headline image
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗
Via Stocktwits
News headline image
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗
Via The Motley Fool
News headline image
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Via The Motley Fool
News headline image
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗
Via The Motley Fool

Frequently Asked Questions

Is Viking Therapeutics, Inc. - Common Stock publicly traded?
Yes, Viking Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Viking Therapeutics, Inc. - Common Stock trade on?
Viking Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Viking Therapeutics, Inc. - Common Stock?
The ticker symbol for Viking Therapeutics, Inc. - Common Stock is VKTX on the Nasdaq Stock Market
What is the current price of Viking Therapeutics, Inc. - Common Stock?
The current price of Viking Therapeutics, Inc. - Common Stock is 33.41
When was Viking Therapeutics, Inc. - Common Stock last traded?
The last trade of Viking Therapeutics, Inc. - Common Stock was at 03/09/26 11:17 AM ET
What is the market capitalization of Viking Therapeutics, Inc. - Common Stock?
The market capitalization of Viking Therapeutics, Inc. - Common Stock is 3.33B
How many shares of Viking Therapeutics, Inc. - Common Stock are outstanding?
Viking Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.